RecruitingPhase 3NCT06722235
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Mezagitamab(drug)
- Enrollment
- 171 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles, California, United States
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States
- Emory University, Atlanta, Georgia, United States
- The University of Iowa, Iowa City, Iowa, United States
- University Of Louisville Brown Cancer Center, Louisville, Kentucky, United States
- American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
- Duke University Hospital, Durham, North Carolina, United States
- East Carolina University, Greenville, North Carolina, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia, Pennsylvania, United States
- Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
- Baylor College of Medicine, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06722235 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation